Andere Sprachen Xintela AB

Aktien

Markt geschlossen - Nasdaq Stockholm Andere Börsenplätze 17:29:44 16.05.2024			% 5 Tage	% 1. Jan.
0.251 ^SEK	-2.71%		-3.46%	-7.38%

28.02.	Xintela AB (publ) meldet Ergebniszahlen für das vierte Quartal zum 31. Dezember 2023	CI
19.02.	Xintela ernennt Lucienne Vonk zum Chief Scientific Officer	CI

Xintela AB publishes Annual Report 2023	17.04.
Xintela: Awaiting results in trials and discussions	29.02.
Xintela AB Year-end Report 2023	28.02.
Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28.02.
Xintela Names New Chief Scientific Officer	20.02.
Xintela appoints Lucienne Vonk as Chief Scientific Officer	19.02.
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	19.02.
Targinta's CEO to BioStock: "Strong interest in ADCs in 2023"	22.01.
Xintela newsletter, No. 1 2024	19.01.
First patient dosed in Xintela's clinical study on difficult-to-heal leg ulcers	21.12.
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	21.12.
Xintela publishes efficacy results with EQSTEM from preclinical equine OA study	20.12.
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	20.12.
Västra Hamnen Corporate Finance initiates coverage of Xintela	04.12.
Xintela’s integrin marker carries hidden value	01.12.
Xintela changes Certified Adviser to Carnegie Investment Bank AB (publ)	30.11.
Xintela AB Interim Report January - September 2023	24.11.
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	24.11.
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study	13.10.23
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	13.10.23

Keine Ergebnisse zu dieser Suche